Cochrane · systematic review · CD009077
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy
Martí‐Carvajal, AJ, Kwong, JSW · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 9 · 64.3%Very low 5 · 35.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCarvedilol compared with placebo for heart failure in patients with Chagas cardiomyopathy
Population: heart failure in patients with Chagas cardiomyopathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Carvedilol vs placebo | RR 0.69 [0.12, 3.88] | 2 studies · 69 participants | Very low Downgraded: risk of bias, imprecision |
Cardiac mortality at 30 days Carvedilol vs placebo | no estimate extracted | 2 studies · 69 participants | Ungraded |
Time‐to‐heart decompensation Carvedilol vs placebo | no estimate extracted | 2 studies · 69 participants | Ungraded |
Disease‐free period (at 30, 60, and 90 days) Carvedilol vs placebo | no estimate extracted | 2 studies · 69 participants | Ungraded |
Overall survival Carvedilol vs placebo | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias |
Quality of life Carvedilol vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Adverse events Carvedilol vs placebo | RR 0.92 [0.67, 1.27] | 1 study · 30 participants | Very low Downgraded: risk of bias |
Rosuvastatin versus placebo for treating heart failure in patients with Chagas cardiomyopathy
Population: chronic heart failure in Chagas cardiomyopathy patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Rosuvastatin vs placebo | no estimate extracted | 1 study · 39 participants | Ungraded |
Cardiac mortality at 30 days Rosuvastatin vs placebo | no estimate extracted | 1 study · 39 participants | Ungraded |
Time to heart decompensation Rosuvastatin vs placebo | no estimate extracted | 1 study · 39 participants | Ungraded |
Disease‐free period at 30, 60 and 90 days Rosuvastatin vs placebo | no estimate extracted | 1 study · 39 participants | Ungraded |
Quality of life Rosuvastatin vs placebo | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Rosuvastatin vs placebo | no estimate extracted | 1 study · 39 participants | Ungraded |
Hospital readmissions (heart failure‐ or adverse event‐related) Rosuvastatin vs placebo | no estimate extracted | 1 study · 39 participants | Ungraded |
Carvedilol versus placebo for treating heart failure in patients with Chagas cardiomyopathy
Population: chronic heart failure in Chagas cardiomyopathy patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall mortality1 Carvedilol vs placebo | RR 0.69 [0.12, 3.88] | 2 studies · 69 participants | Very low Downgraded: risk of bias |
day cardiovascular mortality Carvedilol vs placebo | no estimate extracted | NR | No studies |
Time to heart decompensation Carvedilol vs placebo | no estimate extracted | NR | No studies |
Disease‐free period at 30, 60 and 90 days Carvedilol vs placebo | no estimate extracted | NR | No studies |